PTC Therapeutics Appoints Geoffrey McDonough, M.D., To Board of Directors

  PTC Therapeutics Appoints Geoffrey McDonough, M.D., To Board of Directors

PR Newswire

SOUTH PLAINFIELD, N.J., Nov. 6, 2012

SOUTH PLAINFIELD, N.J., Nov. 6, 2012 /PRNewswire/ --PTC Therapeutics, Inc.
(PTC) today announced the appointment of Geoffrey McDonough, M.D., to the
company's Board of Directors. Dr. McDonough is the President and Chief
Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European
specialty pharmaceutical company developing therapies for patients with rare
disorders and significant medical needs.

(Logo: )

"We are honored to welcome Dr. McDonough to PTC's Board of Directors, his
experience in orphan drug development and commercialization will be
instrumental to PTC as we advance our pipeline and prepare for
commercialization of ataluren in Duchenne/Becker muscular dystrophy and cystic
fibrosis," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC
Therapeutics, Inc. "Dr. McDonough is renowned not only for his broad
experience in genetic disorders but also for his passion for identifying
solutions for patients with unmet medical needs."

Dr. McDonough has been with Sobi since August 2011. Prior to his appointment
as CEO, he held several senior leadership positions at Genzyme Corporation
from 2002 to 2011, most recently as President of Europe, Middle East and
Africa (EMEA). While at Genzyme, Dr. McDonough also served as Senior Vice
President and General Manager, Personalized Genetic Health, and Senior Vice
President, Lysosomal Storage Disease (LSD) Therapeutics. Prior to joining
Genzyme, Dr. McDonough was President and co-founder of Catalyst Medical
Solutions, a developer of software for hospital revenue, medical documentation
and compliance management, served as an adviser to RA Capital Management, and
was a practicing internist and pediatrician. Dr. McDonough received his
medical degree from Harvard Medical School, and a B.Sc. in biology and a B.A.
in philosophy both summa cum laude from the University of North Carolina at
Chapel Hill.

"PTC is a company committed to innovation in the service of patients with
significant unmet medical needs," said Dr. McDonough. "I look forward to
working with PTC to support the advancement of ataluren as well as the
continued growth and development of its broad pipeline."

About PTC Therapeutics
PTC is a biopharmaceutical company focused on the discovery, development and
commercialization of orally administered small-molecule drugs that target
post-transcriptional control processes. Post-transcriptional control processes
regulate the rate and timing of protein production and are of central
importance to proper cellular function. PTC's internally discovered pipeline
addresses multiple therapeutic areas, including rare genetic disorders,
oncology and infectious diseases. PTC has developed proprietary technologies
that it applies in its drug discovery activities and that have served as the
basis for collaborations with leading biopharmaceutical companies. For more
information, visit the company's website at

SOURCE PTC Therapeutics, Inc.

Contact: Jane Baj, PTC Therapeutics, Inc., +1-908-912-9167,;
or Sheryl Seapy, Pure Communications, +1-949-608-0841,
Press spacebar to pause and continue. Press esc to stop.